Working… Menu

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02389517
Recruitment Status : Recruiting
First Posted : March 17, 2015
Last Update Posted : May 1, 2019
National Cancer Institute (NCI)
Multiple Myeloma Research Foundation
Information provided by (Responsible Party):
University of Chicago

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2, 2020
Estimated Study Completion Date : March 2, 2022